IRIS Accounts Production v25.1.4.42 07793447 director 1.1.24 31.12.24 31.12.24 false true false false true false Ordinary A shares 1.00000 Ordinary B Shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh077934472023-12-31077934472024-12-31077934472024-01-012024-12-31077934472022-12-31077934472023-01-012023-12-31077934472023-12-3107793447ns15:EnglandWales2024-01-012024-12-3107793447ns14:PoundSterling2024-01-012024-12-3107793447ns10:Director12024-01-012024-12-3107793447ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3107793447ns10:SmallEntities2024-01-012024-12-3107793447ns10:AuditExemptWithAccountantsReport2024-01-012024-12-3107793447ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3107793447ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3107793447ns10:FullAccounts2024-01-012024-12-3107793447ns10:OrdinaryShareClass12024-01-012024-12-3107793447ns10:OrdinaryShareClass22024-01-012024-12-3107793447ns10:RegisteredOffice2024-01-012024-12-3107793447ns5:CurrentFinancialInstruments2024-12-3107793447ns5:CurrentFinancialInstruments2023-12-3107793447ns5:ShareCapital2024-12-3107793447ns5:ShareCapital2023-12-3107793447ns5:RetainedEarningsAccumulatedLosses2024-12-3107793447ns5:RetainedEarningsAccumulatedLosses2023-12-3107793447ns5:ShareCapital2022-12-3107793447ns5:RetainedEarningsAccumulatedLosses2022-12-3107793447ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3107793447ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3107793447ns5:FurnitureFittings2023-12-3107793447ns5:FurnitureFittings2024-12-3107793447ns5:FurnitureFittings2023-12-3107793447ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3107793447ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3107793447ns10:OrdinaryShareClass12024-12-3107793447ns10:OrdinaryShareClass22024-12-3107793447ns5:RetainedEarningsAccumulatedLosses2023-12-31
REGISTERED NUMBER: 07793447 (England and Wales)















Report of the Director and

Unaudited Financial Statements for the Year Ended 31 December 2024

for

Natupharma UK Limited

Natupharma UK Limited (Registered number: 07793447)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Report of the Director 2

Chartered Accountants' Report 3

Income Statement 4

Other Comprehensive Income 5

Balance Sheet 6

Statement of Changes in Equity 8

Notes to the Financial Statements 9


Natupharma UK Limited

Company Information
for the Year Ended 31 December 2024







DIRECTOR: M Boedtcher-Hansen





REGISTERED OFFICE: Minerva Mill Innovation Centre Office 29
Ground Floor
Station Road
Alcester
Warwickshire
B49 5ET





REGISTERED NUMBER: 07793447 (England and Wales)





ACCOUNTANTS: Krogh & Partners Limited
823 Salisbury House
29 Finsbury Circus
London
EC2M 5QQ

Natupharma UK Limited (Registered number: 07793447)

Report of the Director
for the Year Ended 31 December 2024

The director presents his report with the financial statements of the company for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the company in the year under review was that of wholesale of diet supplements and other food to the health sector in the UK.

DIRECTOR
M Boedtcher-Hansen held office during the whole of the period from 1 January 2024 to the date of this report.

RESULTS AND DIVIDENDS
The Company's loss for the year amounted to GBP 72,183. The director does not recommend the payment of a dividend.

POST BALANCE SHEET EVENTS
No post balance sheet events have occurred since 31 December 2024 which requires reporting or disclosing in the accounts.

AUDITORS
The director has with reference to the exemptions in the Companies Act elected not to appoint auditors.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES
The director is responsible for preparing the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:





M Boedtcher-Hansen - Director


2 June 2025

Chartered Accountants' Report to the Director
on the Unaudited Financial Statements of
Natupharma UK Limited (Registered number: 07793447)


In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Natupharma UK Limited for the year ended 31 December 2024 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the director of Natupharma UK Limited in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Natupharma UK Limited and state those matters that we have agreed to state to the director of Natupharma UK Limited in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Natupharma UK Limited and its director for our work or for this report.

It is your duty to ensure that Natupharma UK Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Natupharma UK Limited. You consider that Natupharma UK Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Natupharma UK Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Krogh & Partners Limited
823 Salisbury House
29 Finsbury Circus
London
EC2M 5QQ


2 June 2025

Natupharma UK Limited (Registered number: 07793447)

Income Statement
for the Year Ended 31 December 2024

2024 2023
Notes £    £   

TURNOVER 2 134,891 187,128

Cost of sales 58,210 81,350
GROSS PROFIT 76,681 105,778

Administrative expenses 144,003 181,317
OPERATING LOSS (67,322 ) (75,539 )

Interest receivable and similar income 525 364
(66,797 ) (75,175 )

Interest payable and similar expenses 5,386 6,761
LOSS BEFORE TAXATION (72,183 ) (81,936 )

Tax on loss 4 - -
LOSS FOR THE FINANCIAL YEAR (72,183 ) (81,936 )

Natupharma UK Limited (Registered number: 07793447)

Other Comprehensive Income
for the Year Ended 31 December 2024

2024 2023
Notes £    £   

LOSS FOR THE YEAR (72,183 ) (81,936 )


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

(72,183

)

(81,936

)

Natupharma UK Limited (Registered number: 07793447)

Balance Sheet
31 December 2024

2024 2023
Notes £    £   
FIXED ASSETS
Tangible assets 5 - -

CURRENT ASSETS
Stocks - 14,718
Debtors 6 4,192 72,915
Cash at bank 36,041 75,072
40,233 162,705
CREDITORS
Amounts falling due within one year 7 1,453,477 1,503,766
NET CURRENT LIABILITIES (1,413,244 ) (1,341,061 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(1,413,244

)

(1,341,061

)

CAPITAL AND RESERVES
Called up share capital 8 100 100
Retained earnings 9 (1,413,344 ) (1,341,161 )
SHAREHOLDERS' FUNDS (1,413,244 ) (1,341,061 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Natupharma UK Limited (Registered number: 07793447)

Balance Sheet - continued
31 December 2024



The financial statements were approved by the director and authorised for issue on 2 June 2025 and were signed by:





M Boedtcher-Hansen - Director


Natupharma UK Limited (Registered number: 07793447)

Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Total
capital earnings equity
£    £    £   
Balance at 1 January 2023 100 (1,259,225 ) (1,259,125 )

Changes in equity
Total comprehensive income - (81,936 ) (81,936 )
Balance at 31 December 2023 100 (1,341,161 ) (1,341,061 )

Changes in equity
Total comprehensive income - (72,183 ) (72,183 )
Balance at 31 December 2024 100 (1,413,344 ) (1,413,244 )

Natupharma UK Limited (Registered number: 07793447)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements have been prepared on a going concern basis assuming the continued financial support of the parent company.

The parent company has confirmed that it will maintain financial support of the company for the foreseeable future to enable the company to continue normal trading operations.

Financial reporting standard 102 - reduced disclosure exemptions
The company has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows.

Accounting policies
The accounting policies of the Company conform to generally accepted practice in the UK. A summary of the more important accounting policies, which have been applied consistently, is set out below.

Turnover
Turnover derives from the principal activity of the Company and is represented by invoiced sales excluding Value Added Tax.

Foreign currencies
Transactions in foreign currencies are recorded using a fixed rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated using the rate of exchange ruling at the balance sheet date. Gains or losses on translation are included in the profit and loss account.

Tangible fixed assets
Tangible assets are stated at cost, net of depreciation and any provision for impairment.

Depreciation on fixed assets is provided at rates estimated to write off the cost amounts, less estimated residual value, of each asset over its expected useful life as follows:

Fixtures and fittings 5 Years

Stock
Stocks are stated at the lower of cost and net realisable value. Net realisable value is based on estimated selling price, less further costs expected to be incurred to completion and disposals. Provisions is made for obsolete, slow-moving or defective items where appropriate.

Debtors
Debtors are valued individually and there are made provision according to this valuation.

Creditors
Creditors are carried at payment or settlement amounts. Where the time value of money is material, creditors are carried at amortized cost.

Taxation

Natupharma UK Limited (Registered number: 07793447)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024
The charge for taxation is based on the result for the year and takes into account taxation deferred because of timing differences between the treatment of certain items for taxation and accounting purposes. Provision is made for deferred tax only to the extent that it is probable that an actual liability or asset will crystallise.

2. TURNOVER

Turnover is attributable to the one principal activity of the company which arose wholly in the United Kingdom.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. TAXATION

Analysis of the tax charge
No liability to UK corporation tax arose for the year ended 31 December 2024 nor for the year ended 31 December 2023.

5. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1 January 2024
and 31 December 2024 55,005
DEPRECIATION
At 1 January 2024
and 31 December 2024 55,005
NET BOOK VALUE
At 31 December 2024 -
At 31 December 2023 -

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors - 69,577
Other debtors 40 1,571
VAT 4,152 1,767
4,192 72,915

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 1,219 435,786
Amounts owed to group undertakings 1,447,802 1,056,681
Social security and other taxes 3,206 9,197
Accruals and deferred income 1,250 2,102
1,453,477 1,503,766

Natupharma UK Limited (Registered number: 07793447)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
90 Ordinary A shares 1 90 90
10 Ordinary B Shares 1 10 10
100 100

9. RESERVES
Retained
earnings
£   

At 1 January 2024 (1,341,161 )
Deficit for the year (72,183 )
At 31 December 2024 (1,413,344 )

10. ULTIMATE CONTROLLING PARTY

The company is controlled by MBH ApS a company registered in Denmark.

MBH ApS prepares financial statements and copies can be obtained from:

Erhvervsstyrelsen
Langelinie Allé 17
2100 København
Denmark